Drug Patent Exclusivity: What the USPTO Study Actually Tells IP Teams, Portfolio Managers, and Generic Challengers
Executive Summary and Key Findings The USPTO’s Drug Patent and Exclusivity Study, produced in collaboration with the FDA at the […]
505(b)(2) Mastery: The Complete IP Strategy Guide for Drug Lifecycle Extension
1. What the 505(b)(2) Pathway Actually Is (and What It Isn’t) The 505(b)(2) New Drug Application (NDA) is a hybrid
505(b)(2) Mastery: The Complete IP Strategy Guide for Drug Lifecycle Extension Read Post »
Generic Drug Market Intelligence: How to Find, Evaluate, and Win Low-Competition Opportunities Before Your Competitors Do
A technical deep dive for pharma IP teams, portfolio managers, R&D leads, and institutional investors Why Most Generic Drug Strategies
Branded Generics ROI: The Complete IP, Pricing, and Market Strategy Playbook
What Branded Generics Actually Are — and Why the Definition Matters for IP Teams The pharmaceutical industry uses ‘branded generic’
Branded Generics ROI: The Complete IP, Pricing, and Market Strategy Playbook Read Post »
FTO Analysis for Drug Repurposing: The Complete IP Strategy Guide
Drug repurposing has a dirty secret. For every sildenafil-to-Viagra success story, there are dozens of ventures that got five years
FTO Analysis for Drug Repurposing: The Complete IP Strategy Guide Read Post »
Divisional Patent Minefields: How Big Pharma Builds Legal Fortresses Around Blockbuster Drugs
Patent cliffs get all the attention. Divisional patents do the real work. When a blockbuster drug faces loss of exclusivity,
How Big Pharma Stretches a 20-Year Patent Into a 40-Year Monopoly
The full playbook of drug patent lifecycle management — and what it costs everyone else Drug companies spend roughly $2.23
How Big Pharma Stretches a 20-Year Patent Into a 40-Year Monopoly Read Post »
How Long Does a Drug Patent Actually Last? The Definitive Analyst’s Guide to Pharmaceutical Patent Duration, Term Extension Mechanics, Regulatory Exclusivity Stacking, and Effective Market Exclusivity Calculation
1. The 20-Year Myth: Why Nominal Term Is the Wrong Starting Number Ask most people in the pharmaceutical business how
Pharma Patent Litigation: The Complete Playbook for IP Teams, Portfolio Managers, and Analysts
Every dollar a brand-name manufacturer recovers in the market traces back, in some way, to the strength and duration of
